Skip to main content
Essex Bio-Technology Limited logo

Essex Bio-Technology Limited — Investor Relations & Filings

Ticker · 1061 HKEX Manufacturing
Open in API
Filings indexed 849 across all filing types
Latest filing 2025-03-04 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1061

About Essex Bio-Technology Limited

http://www.essexbio.com

Essex Bio-Technology Limited is a bio-pharmaceutical company specializing in the development, manufacture, and commercialization of genetically engineered therapeutic Fibroblast Growth Factors (FGFs), particularly recombinant bovine basic FGF (rb-bFGF). The company utilizes recombinant DNA technology to produce biologic drugs aimed at the treatment and healing of surface and organ wounds. Its portfolio includes six flagship biologics approved for a wide range of indications across key therapeutic areas: Ophthalmology, Dermatology, and Wound Healing. Leveraging an in-house R&D platform focused on growth factors and antibodies, the company maintains an active pipeline of projects. Its commercial reach extends to over 14,100 hospitals, supported by 46 regional sales offices.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2025
Regulatory Filings Classification · 1% confidence The document is an HKEX Listing Rule monthly return (Form FF301) detailing movements in authorized, issued, and treasury share capital, including share repurchases. It is a regulatory submission under Chapter 19B of the Exchange Listing Rules rather than an earnings release, management report, or standalone report. It does not present financial results nor announce a specific transaction beyond routine monthly reporting. It is therefore best classified as a general Regulatory Filing (RNS).
2025-03-04 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return (Form FF305) under the Hong Kong Listing Rules, detailing the company’s repurchase and cancellation of its own shares. It is a regulatory disclosure of a share buyback (transaction in own shares), matching the “Transaction in Own Shares” category (POS).
2025-02-26 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return (Form FF305) under Hong Kong Main Board/GEM rules, detailing changes in issued shares, treasury shares, and share repurchases on the Exchange. It provides the number of shares repurchased, treasury share movements, and confirmation of compliance with listing rules. This corresponds directly to a transaction in the company’s own shares (share buybacks and treasury share activities). Therefore, it should be classified under Transaction in Own Shares (Code: POS).
2025-02-10 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) detailing changes in issued shares and treasury shares, specifically share repurchases (40,000 shares) and related confirmations under Main Board/GEM rules. This is a regulatory report of the company buying back (and holding/cancelling) its own shares. This falls squarely under “Transaction in Own Shares” (Code: POS).
2025-02-07 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2025
Regulatory Filings Classification · 1% confidence The document is a Hong Kong Exchange Listing Rules FF301 form titled “Monthly Return for Equity Issuer … on Movements in Securities” showing monthly movements in authorised and issued share capital, share options, repurchases, and other capital changes. It is not an earnings release, annual or interim report, proxy materials, dividend notice, M&A announcement, nor a standalone audit or ESG report. Instead, it is a routine regulatory return submitted to HKEX, fitting the general “Regulatory Filings” fallback category for miscellaneous compliance submissions. Therefore, it should be classified as RNS.
2025-02-04 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return (Form FF305) filed with the Hong Kong Stock Exchange under Listing Rules, detailing an equity issuer’s repurchase and cancellation of its own ordinary shares on specific dates. It is neither an announcement of dividend, nor a director trading report, nor an earnings release, but a regulatory notification of the company buying back its own shares. This best matches the “Transaction in Own Shares” category, code POS.
2025-01-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.